MARKET

RNAC

RNAC

Cartesian
NASDAQ
6.89
-0.13
-1.85%
After Hours: 6.80 -0.09 -1.31% 18:36 11/10 EST
OPEN
6.92
PREV CLOSE
7.02
HIGH
7.28
LOW
6.76
VOLUME
94.86K
TURNOVER
--
52 WEEK HIGH
11.00
52 WEEK LOW
5.60
MARKET CAP
210.17M
P/E (TTM)
-1.3954
1D
5D
1M
3M
1Y
5Y
1D
Cartesian Therapeutics management to meet virtually with Needham
TipRanks · 1d ago
Weekly Report: what happened at RNAC last week (1102-1106)?
Weekly Report · 1d ago
Cartesian Therapeutics: Buy Rating and $25 Price Target Maintained Ahead of AURORA Phase 2b Readout
TipRanks · 4d ago
Cartesian Therapeutics Q3 EPS $(0.38) Beats $(0.95) Estimate
Benzinga · 5d ago
Cartesian Therapeutics GAAP EPS of -$0.38 beats by $0.63
Seeking Alpha · 5d ago
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 6d ago
Weekly Report: what happened at RNAC last week (1026-1030)?
Weekly Report · 11/02 09:19
Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement
Seeking Alpha · 10/29 18:54
More
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.